AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

Another key difference in the study was the dosing. While patients on Fasenra received one 30-mg subcutaneous injection every ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

Under Colorado’s affordability program any time an eligible uninsured Coloradan acquires an auto-injector from a pharmacy in ...

Approximately half of EGPA patients also have adult-onset severe eosinophilic asthma, or SEA, for which Fasenra is only the second biologic approved treatment. Fasenra is now approved as an add-on ...

Amneal Pharmaceuticals has sued Colorado in an effort to block a state law requiring it to provide free generic EpiPens to ...

AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...

Fasenrarecommended for approval in the EU by CHMP for the treatment of eosinophilic granulomatosis with polyangiitis New indication supported by the MANDARA trial which showed nearly ...